GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Jazz Pharmaceuticals

Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.

Healthcare Investors: Here's What You Need to Know About Medical Marijuana

Aphria

British American Tobacco

Frontline

Amplify Alternative Harvest ETF

Nordic American Tankers

OrganiGram Holdings Inc.

Star Bulk Carriers

Tilray Brands

Teekay Tankers

These 2 Stock Market Plays Are Moving Up the Charts in 2021

Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.

The Benefits of Medical Marijuana, for Patients and Your Portfolio

Aurora Cannabis

SNDL Inc.

Multiple high-profile companies may still be on the hunt for a deal.

Why There Could Be at Least 1 More Big Acquisition in the Cannabis Industry This Year

The stock of GW Pharmaceuticals PLC (NAS:GWPH, 30-year Financials) gives every indication of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.

GW Pharmaceuticals PLC Stock Is Estimated To Be Possible Value Trap

These are the top players in the expanding $19.6 billion U.S. marijuana market.

3 Best Marijuana Stocks to Buy in March

The cannabis-based pharmaceutical company agreed to be acquired.

Why GW Pharmaceuticals Stock Rocketed 40.5% in February

Canopy Growth

Innovative Industrial Properties

Global X Cannabis ETF

Village Farms International

AdvisorShares Pure Cannabis ETF 

After soaring to all-time highs last month, exchange traded funds tracking cannabis stocks are coming back down to test a key support line. The post Don't Miss These 2 Ways To Play The Hot Marijuana Stocks Industry appeared first on Investor's Business Daily.

Don't Miss These 2 Ways To Play The Hot Marijuana Stocks Industry

Curaleaf Holdings, Inc.

MedMen Enterprises Inc.

Each of these cannabis stocks blazed higher by between 20% and 208% last month.

The 10 Best Marijuana Stocks in February

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for GW Pharmaceuticals Plc's (NASDAQ: GWPH) Epidyolex (cannabidiol). It is an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC) for patients two years of age and older.

GW Pharmaceuticals' Epidyolex Wins EU Positive Opinion For Seizures Disorder

This month, two groundbreaking deals in cannabis were announced — the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals and the combination of the multi-state operator (MSO) Parallel with the special purpose acquisition company (SPAC), Ceres Acquisition Corp. The proximity of two such large deals in one month begs the question:  Are the GW Pharma — Jazz and Ceres — Parallel deals an important barometer to the direction of cannabis, both in North America and abroad?

The GW Pharma and Parallel Transactions: Where Does the Future of Cannabis go From Here?

Arena Pharmaceuticals

HEXO Corp

New Age Beverages

cbdMD Inc

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

9 Red-Hot Cannabis Stocks Blazing This Week

Amplify Seymour Cannabis ETF

AXS Cannabis ETF

Cambria Cannabis ETF

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Should You Invest in Marijuana Stocks & ETFs Now?

The company's net loss was far narrower than many expected.

GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4

Interest in cannabis stocks has sparked into life this month as London welcomed its first two specialist medical marijuana companies. A surge in share prices was seen around the world last week, as the Reddit-inspired retail investors and YOLO traders jumped aboard the cannabis bandwagon, but a day later and most of the share prices were back to where they started.

London's cannabis sector finally budding two decades after GW Pharma blazed trail

Shares of GW Pharmaceuticals (NASDAQ:GWPH) fell 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 14.29% year over year to ($0.08), which beat the estimate of ($0.60).

GW Pharmaceuticals: Q4 Earnings Insights

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year –

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GW Pharmaceuticals plc - GWPH

Cronos Group

Altria

Constellation Brands

The sector is hot again on the heels of two large deals.

Will There Be More M&A for the Cannabis Industry in 2021?

GameStop

Marijuana stocks have moved higher as hopes increase for wider U.S. legalization, but fell sharply on Feb. 11. Are any pot stocks good buys?

Are Any Marijuana Stocks Good Buys After Wild Swings?

Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.

Cannabis Stocks Rise on Hopes of Federal Legalization in US

1 of the Most Surprising Biotech Acquisitions in Years

Jazz is paying $7.2 million to buy the maker of CBD-derived drug Epidiolex. Is it a smart deal?

4 Green Flags For Jazz Pharmaceuticals' Buyout of GW Pharmaceuticals

Jazz made a bold bet with the acquisition of GW Pharmaceuticals.

Jazz Pharmaceuticals: GW Pharmaceuticals Acquisition Makes Sense

Marijuana stocks are soaring higher on a string of Democratic electoral wins. But not every company in this troubled sector is a winner.

News for GW Pharmaceuticals Stock (GWPH)